Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-19-018787
Filing Date
2019-09-24
Accepted
2019-09-24 15:48:08
Documents
69
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT f10k2019_relmadatherapeutics.htm 10-K 1003713
2 CERTIFICATION f10k2019ex31-1_relmada.htm EX-31.1 7699
3 CERTIFICATION f10k2019ex31-2_relmada.htm EX-31.2 7789
4 CERTIFICATION f10k2019ex32-1_relmada.htm EX-32.1 3434
5 CERTIFICATION f10k2019ex32-2_relmada.htm EX-32.2 3344
  Complete submission text file 0001213900-19-018787.txt   4250289

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE rlmd-20190630.xml EX-101.INS 559356
7 XBRL SCHEMA FILE rlmd-20190630.xsd EX-101.SCH 55461
8 XBRL CALCULATION FILE rlmd-20190630_cal.xml EX-101.CAL 51413
9 XBRL DEFINITION FILE rlmd-20190630_def.xml EX-101.DEF 225630
10 XBRL LABEL FILE rlmd-20190630_lab.xml EX-101.LAB 403048
11 XBRL PRESENTATION FILE rlmd-20190630_pre.xml EX-101.PRE 309371
Mailing Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-K | Act: 34 | File No.: 000-55347 | Film No.: 191110777
SIC: 2834 Pharmaceutical Preparations